0.82
+20.82%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Icecure Medical
Its shares trade under the ticker ICCM. It has been listed since 2 February 2011. In the fiscal year to 31 December 2024, it reported revenue of $3.3m and a net loss of $15.3m. At that date it held total assets of $12.6m and shareholders' equity of $6.9m.
IceCure Medical Ltd. is a commercial stage medical device company. The firm operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 2 Feb 2011
- Employees
- 65
- Website
- icecure-medical.com ↗
- Head office
- 7 HA'ESHEL ST., POB 3163, CAESAREA, 38900
- Incorporated in
- L3
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Non-accelerated filer<br>Emerging growth company
Leadership
Pay as last reported
- Mr. Ron MayronChairman of the Board, since 2017
- Mr. Eyal ShamirChief Executive Officer, Director, since 2016
- Mr. Ronen TsimermanVice President - Finance, Vice President - Operations
- Ms. Elisabeth SadkaVice President-Clinics, Regulations and Quality AssuranceILS 678,000
- Mr. Naum MuchnikVice President - Research & Development
- Ms. Tlalit Bussi Tel-TzureVice President - Business Development & Marketing
- Mr. Yaacov GoldmanExternal Director
- Ms. Sharon LevitaExternal Director
- Mr. Oded TamirExternal Director
- Mr. Doron BirgerIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- IceCure Medical Ltd. has a commercial stage medical device company with 65 employees in Caesarea, Israel.
- ProSense system is a single probe cryoablation system for tumor treatment in breast, lungs, and kidneys.
- MultiSense system is a multi probe cryoablation system for treating multiple tumors simultaneously, not yet commercialized.
Weaknesses
- IceCure Medical Ltd. has not commercialized the MultiSense system for multiple tumor treatment yet.
- The company's business is limited to cryoablation systems using liquid nitrogen for tumor treatment.
- IceCure Medical Ltd. operates in the Health Care sector with a focus on minimally invasive tumor treatments.
Opportunities
- IceCure Medical Ltd. can expand the MultiSense system for multiple tumor treatments once commercialized.
- The Health Care sector offers growth opportunities for minimally invasive tumor treatment technologies.
- Cryoablation systems using liquid nitrogen can be applied to new tumor indications beyond breast, lungs, and kidneys.
Threats
- IceCure Medical Ltd. faces competition from other medical device companies in the Health Care sector.
- The company's reliance on liquid nitrogen technology may face technological advancements in cryoablation systems.
- Regulatory approvals are required for new tumor indications and commercialization of MultiSense system.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.